Literature DB >> 2425014

Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2.

J K Yamamoto, F Barré-Sinoussi, V Bolton, N C Pedersen, M B Gardner.   

Abstract

The effect of human interferons (IFNs) (alpha, beta, and gamma) on the in vitro replication of AIDS viruses (LAV, HTLV-III, and ARV-2) in human peripheral blood lymphocytes was investigated. At the time of peak virus production, IFN-alpha preparations (leukocyte, Namalwa, alpha 1, and alpha 2) at 100 U/ml, suppressed LAV, HTLV-III, and ARV-2 replication as measured by reverse transcriptase (RT) activity by greater than 50%. This suppression was dose dependent and high dosages (500 U/ml) of IFN-alpha resulted in almost complete suppression of RT activities (77-99%). A low dose (100 U/ml) of IFN-beta suppressed all three AIDS viruses by 75%. In contrast, human IFN-gamma at a dose range from 100 U/ml to 500 U/ml had no significant effect on the production of infectious viruses. These results indicate that only IFN-alpha and -beta are effective against LAV, HTLV-III, and ARV-2 replication. A continuous supply of IFN appeared to be essential for the constant suppression of RT activity. In fact, upon termination of single IFN treatment, enhanced virus production resulted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425014     DOI: 10.1089/jir.1986.6.143

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  53 in total

1.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 2.  HIV-1 immunopathogenesis: how good interferon turns bad.

Authors:  Jean-Philippe Herbeuval; Gene M Shearer
Journal:  Clin Immunol       Date:  2006-11-16       Impact factor: 3.969

Review 3.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

4.  Inhibition of HIV replication by CD8+ T cells correlates with CD4 counts and clinical stage of disease.

Authors:  A M Gómez; F M Smaill; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

5.  Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.

Authors:  Shannon R Roff; Missa P Sanou; Mobeen H Rathore; Jay A Levy; Janet K Yamamoto
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.

Authors:  Andrew W Hardy; David R Graham; Gene M Shearer; Jean-Philippe Herbeuval
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

Review 7.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

Review 8.  Innate immunity against HIV: a priority target for HIV prevention research.

Authors:  Persephone Borrow; Robin J Shattock; Annapurna Vyakarnam
Journal:  Retrovirology       Date:  2010-10-11       Impact factor: 4.602

9.  Interferon-alpha mediates restriction of human immunodeficiency virus type-1 replication in primary human macrophages at an early stage of replication.

Authors:  Kelly M Cheney; Áine McKnight
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

10.  Predicting the impact of CD8+ T cell polyfunctionality on HIV disease progression.

Authors:  Frederik Graw; Roland R Regoes
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.